Inovio Pharmaceuticals announced the release of preliminary clinical trial results by its collaborator ChronTech AS of their open label phase II clinical study of ChronVac-C, ChronTech's vaccine to treat hepatitis C virus, or HCV, infection. The study investigated the use of the ChronVac-C DNA vaccine administered with Inovio's MedPulserTM-DDS electroporation device followed by a drug regimen in chronic HCV positive subjects. These initial results do not show a statistically significant difference so far between treatment outcomes of the vaccinated and non-vaccinated groups. The vaccinated group did display an excellent safety profile. In contrast to the previous study, in this subsequent phase II study only two DNA vaccine administrations at the medium dose level used in the phase I study were used to assess the potential for a clinically meaningful result.